Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2018

View Archived Issues

Shionogi reviews highlights of third quarter of fiscal 2017

MSK1 shown as a new prognostic biomarker in ER+ breast cancer

Novel multifunctional vehicle strategy for delivering Cas9-sgRNAs into tumor cells

Takeda updates clinical progress of third quarter of fiscal 2017

INSERM and collaborators patent stromal cell-derived factor 1 inhibitors

Bayer divulges novel TASK-1/3 blockers

Ensoltek describes new peptides acting as RAGE receptor ligands

Advanced Proteome Therapeutics and ImmunoBiochem to collaborate on antibody-drug conjugates

Iovance Biotherapeutics discloses new PD-L1 binding proteins

Bexsero receives second breakthrough therapy designation from the FDA

Novel monoclonal antibodies targeting VE-PTP synthesized at Aerpio Pharmaceuticals

Novel influenza vaccine induces robust long-lasting immunity in mice

Amgen reports product advances for 2017

Ono Pharmaceutical updates key events of third quarter of fiscal 2017

Janssen describes characterization of clinical candidate P2X7 antagonist for mood disorders

Top-line results for ACTION 2 study of natalizumab in acute ischemic stroke

Researchers present phase II data from NabucCO trial on metastatic pancreatic cancer

Verastem submits NDA for duvelisib

FDA approves Biktarvy to treat HIV-1 infection

Case Western, Sangamo awarded grant to advance research on gene-edited T cells to treat HIV

Xcovery starts phase II trial for ensartinib in melanoma patients with ALK alterations

Sage Therapeutics' SAGE-217 given FDA breakthrough therapy designation for major depressive disorder

Aviragen and Vaxart agree to amend merger agreement

YL Biologics reports successful completion of phase III trial of etanercept biosimilar YLB-113

Silenseed initiates phase II study of siG12D LODER in locally advanced pancreatic cancer

Insmed studies INS-1007 in phase II for non-cystic fibrosis bronchiectasis

Symic Biomedical reports MODIFY2 phase II trial results of SB-061 for knee osteoarthritis

GlaxoSmithKline initiates first-in-human study of GSK-2983559

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...